Glucagonoma

Common Name(s)

Glucagonoma

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Glucagonoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Glucagonoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Glucagonoma" returned 50 free, full-text research articles on human participants. First 3 results:

Pancreatic glucagonoma metastasising to the right ovary five years after initial surgery: a case report.
 

Author(s): David Graham Watt, Sanjay Pandanaboyana, Charles Simon Herrington, Iain S Tait

Journal:

 

Glucagonomas of the pancreas are neuroendocrine tumours (NETs) that arise from well-differentiated neuroendocrine cells within the pancreatic islets. They are considered to be aggressive NETs and often have metastases at initial presentation. In contrast localised glucagonoma without ...

Last Updated: 10 Sep 2013

Go To URL
Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome.
 

Author(s): Stephanie A C Halvorson, Erin Gilbert, R Samuel Hopkins, Helen Liu, Charles Lopez, Michael Chu, Marie Martin, Brett Sheppard

Journal: J Gen Intern Med. 2013 Nov;28(11):1525-9.

 

Glucagonomas are slow-growing, rare pancreatic neuroendocrine tumors. They may present with paraneoplastic phenomena known together as the "glucagonoma syndrome." A hallmark sign of this syndrome is a rash known as necrolytic migratory erythema (NME). In this paper, the authors describe ...

Last Updated: 16 Oct 2013

Go To URL
[Diagnosis and treatment of glucagonoma: report of one case].
 

Author(s): Hong Cheng, Maoshan Chen, Guanglun Yang

Journal: Nan Fang Yi Ke Da Xue Xue Bao. 2013 Apr;33(4):618-insidebackcover.

 

glucagonoma is a rare islet alpha-cell tumor. We report a case of glucagonoma in a 55-year-old male patient with such clinical findings of necrolytic migratory erythema, diabetes mellitus, body weight loss, and anemia. CT examination found a space-occupying lesion in the pancreas, ...

Last Updated: 6 May 2013

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Glucagonoma" returned 4 free, full-text review articles on human participants. First 3 results:

The glucagonoma syndrome and necrolytic migratory erythema: a clinical review.
 

Author(s): Andre P van Beek, Ellen R M de Haas, Willem A van Vloten, Cees J M Lips, Janine F M Roijers, Marijke R Canninga-van Dijk

Journal: Eur. J. Endocrinol.. 2004 Nov;151(5):531-7.

 

The glucagonoma syndrome is a rare disease in which a typical skin disorder, necrolytic migratory erythema, is often one of the first presenting symptoms. Weight loss and diabetes mellitus are two other prevalent characteristics of this syndrome. Necrolytic migratory erythema belongs ...

Last Updated: 12 Nov 2004

Go To URL
Clinical experience in diagnosis and treatment of glucagonoma syndrome.
 

Author(s): Min Zhang, Xiao Xu, Yan Shen, Zhen-Hua Hu, Li-Ming Wu, Shu-Sen Zheng

Journal: HBPD INT. 2004 Aug;3(3):473-5.

 

Pancreatic endocrine tumors are uncommon neoplasms and can lead to systemic disorder including glucagonoma syndrome, a very rare prototypical paraneoplastic phenomenon. The aim of this study was to assess the diagnosis and surgical strategy for the treatment of glucagonoma syndrome.

Last Updated: 17 Aug 2004

Go To URL
Glucagonoma associated with calculous pancreatitis.
 

Author(s): C Mao, P M Pour, J M Howard

Journal: HPB Surg. 1996 ;9(2):77-81.

 

A Patient with a glucagonoma associated with calculous pancreatitis is reported. The authors know of only one other such patient. Because the calculous pancreatitis developed both upstream and downstream from the tumor, it cannot be attributed to obstruction of the pancreatic duct ...

Last Updated: 27 Jan 1997

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
 

Status: Recruiting

Condition Summary: Gastrinoma; Glucagonoma; Insulinoma; Liver Metastases; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma

 

Last Updated: 24 Jul 2014

Go to URL
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
 

Status: Recruiting

Condition Summary: Estrogen Receptor-positive Breast Cancer; Gastrinoma; Glucagonoma; HER2-negative Breast Cancer; Insulinoma; Mucositis; Oral Complications; Pancreatic Polypeptide Tumor; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Recurrent Islet Cell Carcinoma; Recurrent Renal Cell Cancer; Somatostatinoma; Stage III Renal Cell Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Stage IV Renal Cell Cancer

 

Last Updated: 4 Nov 2014

Go to URL
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
 

Status: Recruiting

Condition Summary: Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma

 

Last Updated: 11 Nov 2014

Go to URL